Canada approved a generic semaglutide for sale in the country, marking the first G7 offering of a generic version of Novo Nordisk’s Wegovy/Ozempic. The product is produced by Dr. Reddy’s Laboratories and is prescription-only, with the Canadian government also considering additional generic alternatives. The move lands as oral GLP-1 competition accelerates, with Eli Lilly pushing orforglipron into the oral GLP-1 conversation. In parallel, Teva has previously announced a generic alternative for liraglutide, adding pressure on branded GLP-1 pricing strategies. For biotech and pharma stakeholders, the key question is not just entry timing, but how fast pricing leverage spreads beyond the first approved generic product—especially in markets where federal procurement and insurer formularies can quickly propagate lower-cost options. The approval also highlights the policy and manufacturing gap between name-brand pricing and estimated peptide production costs, which can reshape access if more generics follow across geographies.